Kite’s Tecartus reported encouraging data in R/R Mantle Cell Lymphoma

CAR-T Digest - August 2020

Jun 06, 2023: Tecartus / R/R Mantle Cell Lymphoma / Kite: Reported encouraging data

Tecartus in patients with R/R MCL, showed consistently high complete response and overall response rates, regardless of the type of prior treatment
In CIBMTR Registry Analysis, Tecartus also demonstrates an 88% Complete Response Rate and 94% Overall Response rate in Second-and-Third-Line Treatment
With a median follow-up of 12 months, ORR was 90%, and PFS and OS rates were 61% and 74% respectively
In a multivariate analysis of patients who received Tecartus in earlier lines of therapy, data showed 94% ORR